Itacitinib (INCB039110)

INCB039110 · Incyte Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Itacitinib (INCB039110), covering 2023-09-13 to 2023-09-13. Get the full timeline:

Most recent: Clinical Trial Update: Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer [Phase 2]